EcoDrugPlus

Proteasome 26s Subunit, Non-Atpase 8

Ensembl ID : ENSCSEG00000007124
Gene Symbol: PSMD8
1 Cross references
213 Possible Orthologues:

Proteasome Subunit Alpha Type-4-Like

Ensembl ID : ENSCSEG00000001918
Gene Symbol: LOC103379914
3 Cross references
199 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSCSEG00000021119
Gene Symbol: PSMB11
2 Cross references
170 Possible Orthologues:

Proteasome Subunit Beta Type-5

Ensembl ID : ENSCSEG00000021118
Gene Symbol: LOC103396604
3 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSCSEG00000017959
Gene Symbol: LOC103389149
3 Cross references
172 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSCSEG00000007406
Gene Symbol: LOC103389639
3 Cross references
215 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSCSEG00000021126
Gene Symbol: PRMT5
3 Cross references
199 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSCSEG00000003776
Gene Symbol: LOC103381205
3 Cross references
203 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSCSEG00000010211
Gene Symbol: PRKCA
3 Cross references
212 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSCSEG00000018731
Gene Symbol: PRKCB
4 Cross references
213 Possible Orthologues:

Protein Kinase C Beta Type-Like

Ensembl ID : ENSCSEG00000004071
Gene Symbol: LOC103383625
3 Cross references
205 Possible Orthologues:

Protein Kinase C Delta

Ensembl ID : ENSCSEG00000005232
Gene Symbol: PRKCD
3 Cross references
204 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).